National Pension Service Lowers Stock Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

National Pension Service reduced its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 2.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 3,084,889 shares of the company’s stock after selling 85,751 shares during the period. National Pension Service’s holdings in Teva Pharmaceutical Industries were worth $67,991,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of TEVA. FMR LLC increased its holdings in Teva Pharmaceutical Industries by 49.5% in the 3rd quarter. FMR LLC now owns 62,740,763 shares of the company’s stock valued at $1,130,589,000 after acquiring an additional 20,762,226 shares during the last quarter. Janus Henderson Group PLC increased its holdings in Teva Pharmaceutical Industries by 7,945.2% in the 3rd quarter. Janus Henderson Group PLC now owns 4,791,937 shares of the company’s stock valued at $86,350,000 after acquiring an additional 4,732,374 shares during the last quarter. Todd Asset Management LLC bought a new stake in Teva Pharmaceutical Industries in the 4th quarter valued at $58,243,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in Teva Pharmaceutical Industries by 237.5% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,377,517 shares of the company’s stock valued at $60,863,000 after acquiring an additional 2,376,668 shares during the last quarter. Finally, Clal Insurance Enterprises Holdings Ltd increased its holdings in Teva Pharmaceutical Industries by 6.8% in the 3rd quarter. Clal Insurance Enterprises Holdings Ltd now owns 34,543,812 shares of the company’s stock valued at $621,337,000 after acquiring an additional 2,204,623 shares during the last quarter. 54.05% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have issued reports on TEVA shares. StockNews.com downgraded shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. Piper Sandler boosted their target price on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a report on Friday, January 17th. UBS Group reduced their target price on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a report on Thursday, January 30th. Finally, Barclays reduced their target price on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a report on Thursday, January 30th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $23.57.

Teva Pharmaceutical Industries Stock Performance

Shares of NYSE:TEVA opened at $16.32 on Friday. The company has a market capitalization of $18.49 billion, a price-to-earnings ratio of -11.26, a PEG ratio of 1.44 and a beta of 0.71. Teva Pharmaceutical Industries Limited has a 12 month low of $12.51 and a 12 month high of $22.80. The firm’s 50-day moving average is $19.75 and its 200 day moving average is $18.48. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. Research analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current year.

Insider Activity at Teva Pharmaceutical Industries

In related news, Director Roberto Mignone sold 286,000 shares of the company’s stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the transaction, the director now directly owns 695,000 shares in the company, valued at approximately $15,296,950. This represents a 29.15 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.55% of the stock is currently owned by insiders.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.